Tag - ICAD

Markets

BTIG cuts iCAD PT to $12 from $25; maintains buy rating

BTIG slashed its price target for iCAD (NASDAQ:ICAD) to $12 from $25 but maintained its “buy” rating, ahead of the company’s fourth quarter earnings report next week. The stock closed at $4.97 on Feb. 23. In a...

February 23, 2022

Markets

BTIG starts iCAD at buy; PT $25

BTIG initiated coverage of iCAD (NASDAQ:ICAD) with a “buy” rating and a price target of $25. The stock closed at $19.35 on March 22. iCAD is a medical technology company focused on cancer care, offering both cutting...

March 23, 2021

Tag - ICAD

BTIG cuts iCAD PT to $12 from $25; maintains buy rating

BTIG starts iCAD at buy; PT $25

General

More